Trastuzumab for example is an anti-HER2 monoclonal antibody used to treat breast cancer, and has been shown to make HER2+ tumour cells more susceptible to antibody dependent and T-cell mediated cytotoxicity (115, 116). The gene discussed is ERBB2; the disease is breast carcinoma.